A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

Terminated

• Conditions: Growth Hormone Deficiency
• Interventions: Device: NuSpin; Drug: Somatropin

• Registration Number: NCT01243892
• Lead Sponsor: Genentech, Inc.

Brief Summary

This is a Phase IV, open label, case-controlled, observational study to evaluate the age-adjusted cumulative height velocity in pre-pubertal isolated growth hormone deficient (IGHD) and idiopathic short stature (ISS) participants receiving daily doses of somatropin (recombinant human growth hormone \[rhGH\]; Nutropin) using NuSpin device compared to historical controls from the national cooperative growth study (NCGS).

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-17
• Study First Submitted QC: 2010-11-18
• Study First Posted: 2010-11-19
• Primary Completion: 2011-08
• Study Completion: 2011-08
• Status Verified: 2016-10
• Results First Submitted: 2016-10-07
• Results First Submitted QC: 2016-10-07
• Last Update Submitted: 2016-10-07
• Results First Posted: 2016-12-01
• Last Update Posted: 2016-12-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• Bone age less than or equal to (</=) 8 years (females) or </= 10 years (males) as determined by x-ray of the left hand and wrist obtained within six months before enrollment
• Prepubertal males and females by physical exam
• Naive to rhGH therapy
• Diagnosis of IGHD or ISS by standard pharmacologic testing and no other discernable etiology for short stature
• Height standard deviation score (Ht SDS) </= -1.5 (</= 5th percentile) for IGHD participants; Ht SDS </= -2.25 (</= 1.2 percentile) for ISS participants

Exclusion Criteria

• Short stature etiologies other than IGHD or ISS
• Participants receiving chronic corticosteroid therapy (greater than [>] 3 months) for other medical conditions
• Participants with active malignancy or any other condition that the investigator believes would pose a significant hazard to the participant if rhGH were initiated
• Females with turner syndrome
• Any previous rhGH treatment
• Participation in another simultaneous medical investigation or trial
• Pediatric participants with closed epiphyses
• Participants prescribed rhGH doses outside the variance of NCGS control participant dosing

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cohort 1: IGHD participants	NuSpin	Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid \[DNA\] origin) (recombinant human growth hormone \[rhGH\]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
Cohort 2: ISS participants	NuSpin	Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
Cohort 1: IGHD participants	Somatropin	Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid \[DNA\] origin) (recombinant human growth hormone \[rhGH\]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
Cohort 2: ISS participants	Somatropin	Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.

Primary Outcome Measures

Name	Time	Method
Annualized Height Velocity in Response to rhGH Treatment Using the NuSpin Device After Two Years of Treatment	Baseline up to Month 24 (Year 2)	The annualized height velocity (cm per year \[cm/yr\]) over 2 years was calculated as: \[(height in cm at t24 minus (-) height in cm at t0) divided by (date at t24 - date at t0)\] multiplied by 365.25, where, t0 is the baseline measurement visit and t24 is the 2-year measurement visit.

Secondary Outcome Measures

Name	Time	Method
Annualized Height Velocity in Response to rhGH Treatment Using the NuSpin Device for First Year of Treatment	Baseline up to Month 12 (Year 1)	The annualized height velocity (cm/yr) after 1 year was calculated as: \[(height in cm at t12 - height in cm at t0) divided by (date at t12 - date at t0)\] multiplied by 365.25, where, t0 is the baseline measurement visit and t12 is the 1-year measurement visit.
Annualized Height Velocity in Response to rhGH Treatment Using the NuSpin Device During the Second Year of Therapy	Month 12 to Month 24 (Year 1 to Year 2)	The annualized height velocity (cm/yr) for second year was calculated as: \[(height in cm at t24 - height in cm at t12) divided by (date at t24 - date at t12)\] multiplied by 365.25, where, t12 is the 1-year measurement visit and t24 is the 2-year measurement visit.